Molecular targeting of proteins by L-homocysteine: Mechanistic implications for vascular disease

Antioxidants and Redox Signaling

Volumn 9, Issue 11, 2007, Pages 1883-1898

  Glushchenko, Alla V ^a   Jacobsen, Donald W ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR 5A; CELL PROTEIN; COLLAGEN; CYSTEINE; DIMETHYLARGININASE; FIBRILLIN 1; FIBRIN; FIBRONECTIN; GLUTATHIONE PEROXIDASE; HOMOCYSTEINE; LIPOCORTIN 2; LIPOPROTEIN A; MEMBRANE PROTEIN; METALLOPROTEINASE; METALLOTHIONEIN; PREALBUMIN; SUPEROXIDE DISMUTASE; THIOL DERIVATIVE; ZINC;

ATHEROGENESIS; CARDIOVASCULAR RISK; CYTOTOXICITY; DISULFIDE BOND; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; HUMAN; HYPERHOMOCYSTEINEMIA; NONHUMAN; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; VASCULAR DISEASE;

ANIMALS; BLOOD PROTEINS; HOMOCYSTEINE; HUMANS; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; VASCULAR DISEASES;

EID: 35448970996     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2007.1809     Document Type: Review

References (140)

1. Austin RC, Lentz SR, and Werstuck GH. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ 11(suppl 1): S56-S64, 2004.
2. Banhegyi G, Csala M, Nagy G, Sorrentino V, Fulceri R, and Benedetti A. Evidence for the transport of glutathione through ryanodine receptor channel type 1. Biochem J 376: 807-812, 2003.
3. Barbato JC, Catanescu O, Murray K, DiBello PM, and Jacobsen DW. Targeting of metallothionein by L-homocysteine: a novel mechanism for disruption of zinc and redox homeostasis. Arterioscler Thromb Vasc Biol 27: 49-54, 2007.
4. Beckmann AM and Wilce PA. Egr transcription factors in the nervous system. Neurochem Int 31: 477-510; discussion 517-476, 1997.
5. Benson MD. Amyloidosis. In: The metabolic and molecular bases of inherited disease, edited by Scriver CR, Beaudet AL, Sly WS, and Valle D. New York: McGraw-Hill Medical Publishing Division, 2001, pp. 5345-5378.
6. Bescond A, Augier T, Chareyre C, Garáon D, Hornebeck W, and Charpiot P. Influence of homocysteine on matrix metalloproteinase-2: activation and activity. Biochem Biophys Res Commun 263: 498-503, 1999.
7. Böger RH, Bode-Böger SM, Sydow K, Heistad DD, and Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 20: 1557-1564, 2000.
8. Bostom AG and Culleton BF. Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 10: 891-900, 1999.
9. Braakman I, Helenius J, and Helenius A. Role of ATP and disulphide bonds during protein folding in the endoplasmic reticulum. Nature 356: 260-262, 1992.
10. Büdy B, Sengupta S, DiBello PM, Kinter M, and Jacobsen DW. A facile synthesis of homocysteine-cysteine mixed disulfide. Anal Biochem 291: 303-305, 2001.
11. Burke AP, Fonseca V, Kolodgie F, Zieske A, Fink L, and Virmani R. Increased serum homocysteine and sudden death resulting from coronary atherosclerosis with fibrous plaques. Arterioscler Thromb Vasc Biol 22: 1936-1941, 2002.
12. Cai Y, Zhang C, Nawa T, Aso T, Tanaka M, Oshiro S, Ichijo H, and Kitajima S. Homocysteine-responsive ATF3 gene expression in human vascular endothelial cells: activation of c-Jun NH(2)-terminal kinase and promoter response element. Blood 96: 2140-2148, 2000.
13. Carmel R and Jacobsen DW (Eds). Homocysteine in health and disease. Cambridge, UK: Cambridge University Press, 2001, p. 510.
14. Chakravarthi S, Jessop CE, and Bulleid NJ. The role of glutathione in disulphide bond formation and endoplasmic-reticulum-generated oxidative stress. EMBO Rep 7: 271-275, 2006.
15. Chen P, Poddar R, Tipa EV, DiBello PM, Moravec CD, Robinson K, Green R, Kruger WD, Garrow TA, and Jacobsen DW. Homocysteine metabolism in cardiovascular cells and tissues: implications for hyperhomocysteinemia and cardiovascular disease. Adv Enzyme Regul 39: 93-109, 1999.
16. Christodoulou J, Sadler P, and Tucker A. 1H-NMR of albumin in human blood plasma: drug binding and redox reactions at Cys 34. FEBS Lett 376: 1-5, 1995.
17. Christodoulou J, Sadler P, and Tucker A. A new structural transition of serum albumin dependent on the state of Cys 34: detection by 1H-NMR spectroscopy. Eur J Biochem 225: 363-368, 1994.
18. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, and Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 55: 1449-1455, 1998.
19. Cornwell GG, Murdoch WL, Kyle RA, Westermark P, and Pitkanen P. Frequency and distribution of senile cardiovascular amyloid: a clinicopathologic correlation. Am J Med 75: 618-623, 1983.
20. Daly S, Cotter A, Molloy AE, and Scott J. Homocysteine and folic acid: implications for pregnancy. Semin Vasc Med 5: 190-200, 2005.
21. Eichinger S, Stümpflen A, Hirschl M, Bialonczyk C, Herkner K, Stain M, Schneider B, Pabinger I, Lechner K, and Kyrle PA. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 80: 566-569, 1998.
22. Estes SD, Stoler DL, and Anderson GR. Normal fibroblasts induce the C/EBP beta and ATF-4 bZIP transcription factors in response to anoxia. Exp Cell Res 220: 47-54, 1995.
23. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1: 228-237, 1990.
24. Foody JM, Milberg JA, Robinson K, Pearce GL, Jacobsen DW, and Sprecher DL. Homocysteine and lipoprotein(a) interact to increase CAD risk in young men and women. Arterioscler Thromb Vasc Biol 20: 493-499, 2000.
25. Frey D, Braun O, Briand C, Vasak M, and Grutter MG. Structure of the mammalian NOS regulator dimethylarginine dimethylaminohydrolase: a basis for the design of specific inhibitors. Structure 14: 901-911, 2006.
26. Fryer RH, Wilson BD, Gubler GM, Fitzgerald LA, and Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 13: 1327-1333, 1993.
27. Georgopoulos C, and Welch WJ. Role of the major heat shock proteins as molecular chaperones. Annu Rev Cell Biol 9: 601-634, 1993.
28. Gorlach A, Klappa P, and Kietzmann T. The endoplasmic reticulum: folding, calcium homeostasis, signaling, and redox control. Antioxid Redox Signal 8: 1391-1418, 2006.
29. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 91: 2873-2879, 1993.
30. Hajjar KA, Harpel PC, Jaffe EA, and Nachman RL. Binding of plasminogen to cultured human endothelial cells. J Biol Chem 261: 11656-11662, 1986.
31. Hajjar KA and Jacovina AT. Modulation of annexin II by homocysteine: implications for atherothrombosis. J Invest Med 46: 364-369, 1998.
32. Hajjar KA, Mauri L, Jacovina AT, Zhong FM, Mirza UA, Padovan JC, and Chait BT. Tissue plasminogen activator binding to the annexin II tail domain: direct modulation by homocysteine. J Biol Chem 273: 9987-9993, 1998.
33. Hamer DH. Metallothionein. Annu Rev Biochem 55: 913-951, 1986.
34. Handy DE, Zhang Y, and Loscalzo J. Homocysteine down-regulates cellular glutathione peroxidase (GPx1) by decreasing translation. J Biol Chem 280: 15518-15525, 2005.
35. Harding HP, Calfon M, Urano F, Novoa I, and Ron D. Transcriptional and translational control in the mammalian unfolded protein response. Annu Rev Cell Dev Biol 18: 575-599, 2002.
36. Harpel PC, Chang VT, and Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci U S A 89: 10193-10197, 1992.
37. Hayashi T, Honda G, and Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 79: 2930-2936, 1992.
38. Haynes CM, Titus EA, and Cooper AA. Degradation of misfolded proteins prevents ER-derived oxidative stress and cell death. Mol Cell 15: 767-776, 2004.
39. He XM and Carter DC. Atomic structure and chemistry of human serum albumin. Nature 358: 209-215, 1992.
40. Herrmann W, Quast S, Ellgass A, Wolter K, Kiessig ST, Molinari E, and Riegel W. An increased serum level of free Apo(a) in renal patients is more striking than that of Lp(a) and is influenced by homocysteine. Nephron 85: 41-49, 2000.
41. Hofmann MA, Lolla E, Lu Y, Ryu Gleason M, Wolf BM, Tanji N, Ferran LJ Jr, Kohl B, Rao V, Kisiel W, Stern DM, and Schmidt AM. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 107: 675-683, 2001.
42. Hossain GS, vanThienen JV, Werstuck G, Zhou J, Sood SK, Dickhout JG, de Koning ABL, Tang D, Wu D, Falk E, Poddar R, Jacobsen DW, Zhang K, Kaufman RJ, and Austin RC. TDAGG51 is induced by homocysteine, promotes detachment-mediated programmed cell death and contributes to the development of atherosclerosis in hyperhomocysteinemia. J Biol Chem 278: 30317-30327, 2003.
43. Huang R-FS, Hsu Y-C, Lin H-L, and Yang FL. Folate depletion and elevated plasma homocysteine promote oxidative stress in rat livers. J Nutr 131: 33-38, 2001.
44. Hubmacher D, Tiedemann K, Bartels R, Brinckmann J, Vollbrandt T, Batge B, Notbohm H, and Reinhardt DP. Modification of the structure and function of fibrillin-1 by homocysteine suggests a potential pathogenetic mechanism in homocystinuria. J Biol Chem 280: 34946-34955, 2005.
45. Jacob C, Maret W, and Vallee BL. Control of zinc transfer between thionein, metallothionein, and zinc proteins. Proc Natl Acad Sci U S A 95: 3489-3494, 1998.
46. Jacobsen DW. Hyperhomocysteinemia and oxidative stress: time for a reality check? Arterioscler Thromb Vasc Biol 20: 1182-1184, 2000.
47. Jakubowski H. Molecular basis of homocysteine toxicity in humans. Cell Mol Life Sci 61: 470-487, 2004.
48. Jakubowski H. Pathophysiological consequences of homocysteine excess. J Nutr 136: 1741S-1749S, 2006.
49. Jiang LJ, Maret W, and Vallee BL. The glutathione redox couple modulates zinc transfer from metallothionein to zinc-depleted sorbitol dehydrogenase. Proc Natl Acad Sci U S A 95: 3483-3488, 1998.
50. Kang S-S, Wong PWK, and Becker N. Protein-bound homocyst(e)ine in normal subjects and in patients with homocystinuria. Pediatr Res 13: 1141-1143, 1979.
51. Kang S-S, Wong PWK, Cook HY, Norusis M, and Messer JV. Protein-bound homocysteine: a possible risk factor for coronary artery disease. J Clin Invest 77: 1482-1486, 1986.
52. Kaufman RJ. Orchestrating the unfolded protein response in health and disease. J Clin Invest 110: 1389-1398, 2002.
53. Kaufman RJ, Scheuner D, Schroder M, Shen X, Lee K, Liu CY, and Arnold SM. The unfolded protein response in nutrient sensing and differentiation. Nat Rev Mol Cell Biol 3: 411-421, 2002.
54. Kishikawa M, Nakanishi T, Miyazaki A, and Shimizu A. A simple and reliable method of detecting variant transthyretins by multidimensional liquid chromatography coupled to electrospray ionization mass spectrometry. Amyloid: Int J Exp Clin Invest 6: 48-53, 1999.
55. Kokame K, Agarwala KL, Kato H, and Miyata T. Herp, a new ubiquitin-like membrane protein induced by endoplasmic reticulum stress. J Biol Chem 275: 32846-32853, 2000.
56. Kokame K, Kato H, and Miyata T. Homocysteine-respondent genes in vascular endothelial cells identified by differential display analysis: GRP78/BiP and novel genes. J Biol Chem 271: 29659-29665, 1996.
57. Lawrence de Koning AB, Werstuck GH, Zhou J, and Austin RC. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem 36: 431-441, 2003.
58. Le Gall S, Neuhof A, and Rapoport T. The endoplasmic reticulum membrane is permeable to small molecules. Mol Biol Cell 15: 447-455, 2004.
59. Lee AS. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci 26: 504-510, 2001.
60. Lentz SR. Homocysteine and cardiovascular physiology. In: Homocysteine in health and disease, edited by Carmel R and Jacobsen DW. Cambridge, UK: Cambridge University Press, 2001, pp. 441-450.
61. Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 3: 1646-1654, 2005.
62. Lentz SR, Piegors DJ, Fernández JA, Erger RA, Arning E, and Malinow MR. Effects of hyperhomocysteinemia on protein C activation and activity. Blood 100: 2108-2112, 2002.
63. Lentz SR and Sadler JE. Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood 81: 683-689, 1993.
64. Lentz SR and Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 88: 1906-1914, 1991.
65. Lenz B, Bleich S, Beutler S, Schlierf B, Schwager K, Reulbach U, Kornhuber J, and Bonsch D. Homocysteine regulates expression of Herp by DNA methylation involving the AARE and CREB binding sites. Exp Cell Res 312: 4049-4055, 2006.
66. Li X, Chen H, and Epstein PN. Metallothionein protects islets from hypoxia and extends islet graft survival by scavenging most kinds of reactive oxygen species. J Biol Chem 279: 765-771, 2004.
67. Lim A, Sengupta S, McComb ME, Theberge R, Wilson WG, Costello CE, and Jacobsen DW. In vitro and In vivo interactions of homocysteine with human plasma transthyretin. J Biol Chem 278: 49707-49713, 2003.
68. Lubec B, Labudova O, Hoeger H, Muehl A, Fang-Kircher S, Marx M, Mosgoeller W, and Gialamas J. Homocysteine increases cyclin-dependent kinase in aortic rat tissue. Circulation 94: 2620-2625, 1996.
69. Ma Y and Hendershot LM. ER chaperone functions during normal and stress conditions. J Chem Neuroanat 28: 51-65, 2004.
70. Ma Y and Hendershot LM. The mammalian endoplasmic reticulum as a sensor for cellular stress. Cell Stress Chaperones 7: 222-229, 2002.
71. Majors A, Ehrhart LA, and Pezacka EH. Homocysteine as a risk factor for vascular disease: enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 17: 2074-2081, 1997.
72. Majors AK, Sengupta S, Jacobsen DW, and Pyeritz RE. Upregulation of smooth muscle cell collagen production by homocysteine-insight into the pathogenesis of homocystinuria. Mol Genet Metab 76: 92-99, 2002.
73. Majors AK, Sengupta S, Willard B, Kinter MT, Pyeritz RE, and Jacobsen DW. Homocysteine binds to human plasma fibronectin and inhibits its interaction with fibrin. Arterioscler Thromb Vasc Biol 22: 1354-1359, 2002.
74. Mansoor MA, Bergmark C, Svardal AM, Lonning PE, and Ueland PM. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with early-onset peripheral vascular disease. Homocysteine and peripheral vascular disease. Arterioscler Thromb Vasc Biol 15: 232-240, 1995.
75. Mansoor MA, Svardal AM, and Ueland PM. Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma. Anal Biochem 200: 218-229, 1992.
76. Mansoor MA, Ueland PM, Aarsland A, and Svardal AM. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with homocystinuria. Metabolism 42: 1481-1485, 1993.
77. Marciniak SJ and Ron D. Endoplasmic reticulum stress signaling in disease. Physiol Rev 86: 1133-1149, 2006.
78. Maret W. Oxidative metal release from metallothionein via zinc-thiol/disulfide interchange. Proc Natl Acad Sci U S A 91: 237-241, 1994.
79. Maret W and Vallee BL. Thiolate ligands in metallothionein confer redox activity on zinc clusters. Proc Natl Acad Sci U S A 95: 3478-3482, 1998.
80. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 56: 111-128, 1969.
81. McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE, Hannan MT, Cupples LA, and Kiel DP. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 350: 2042-2049, 2004.
82. Moat SJ, Lang D, McDowell IF, Clarke ZL, Madhavan AK, Lewis MJ, and Goodfellow J. Folate, homocysteine, endothelial function and cardiovascular disease. J Nutr Biochem 15: 64-79, 2004.
83. Mudd SH, Levy HL, and Kraus JP. Disorders of transsulfuration. In: The metabolic and molecular bases of inherited disease, edited by Scriver CR, Beaudet AL, Sly WS, and Valle D. New York: McGraw-Hill Medical Publishing Division, 2001, pp. 2007-2056.
84. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GHJ, Bromberg IL, Cerone R, Fowler B, Grobe H, Schmidt H, and Schweitzer L. The natural history of homocystinuria due to cystathionine-β- synthase deficiency. Am J Hum Genet 37: 1-31, 1985.
85. Mujumdar VS, Hayden MR, and Tyagi SC. Homocyst(e)ine induces calcium second messenger in vascular smooth muscle cells. J Cell Physiol 183: 28-36, 2000.
86. Murphy G and Docherty JP. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 7: 120-125, 1992.
87. Nettesheim DG, Engeseth HR, and Otvos JD. Products of metal exchange reactions of metallothionein. Biochemistry 24: 6744-6751, 1985.
88. Nishinaga M, Ozawa T, and Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 92: 1381-1386, 1993.
89. Nishio E and Watanabe Y. Homocysteine as a modulator of platelet-derived growth factor action in vascular smooth muscle cells: a possible role for hydrogen peroxide. Br J Pharmacol 122: 269-274, 1997.
90. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, and Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337: 230-236, 1997.
91. Nygård O, Vollset SE, Refsum H, Brattström L, and Ueland PM. Total homocysteine and cardiovascular disease. J Intern Med 246: 425-454, 1999.
92. Outinen PA, Sood SK, Liaw PCY, Sarge KD, Maeda N, Hirsh J, Ribau J, Podor TJ, Weitz JI, and Austin RC. Characterization of the stress-inducing effects of homocysteine. Biochem J 332: 213-221, 1998.
93. Outinen PA, Sood SK, Pfeifer SI, Pamidi S, Podor TJ, Li J, Weitz JI, and Austin RC. Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. Blood 94: 959-967, 1999.
94. Pahl HL. Signal transduction from the endoplasmic reticulum to the cell nucleus. Physiol Rev 79: 683-701, 1999.
95. Palmiter RD. The elusive function of metallothioneins. Proc Natl Acad Sci U S A 95: 8428-8430, 1998.
96. Peters T Jr. All about albumin: biochemistry, genetics, and medical applications. San Diego: Academic Press, 1996, p. 432.
97. Poddar R, Sivasubramanian N, DiBello PM, Robinson K, and Jacobsen DW. Homocysteine induces expression and secretion of MCP-1 and IL-8 in human aortic endothelial cells: implications for vascular disease. Circulation 103: 2717-2723, 2001.
98. Pyeritz RE. The Marfan syndrome. Annu Rev Med 51: 481-510, 2000.
99. Rao RV, Ellerby HM, and Bredesen DE. Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ 11: 372-380, 2004.
100. Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, and Lee AS. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem 278: 20915-20924, 2003.
101. Refsum H, Helland S, and Ueland PM. Radioenzymic determination of homocysteine in plasma and urine. Clin Chem 31: 624-628, 1985.
102. Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, Johnston C, Engbaek F, Schneede J, McPartlin C, and Scott JM. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 50: 3-32, 2004.
103. Rizzuto R, Pinton P, Ferrari D, Chami M, Szabadkai G, Magalhaes PJ, Di Virgilio F, and Pozzan T. Calcium and apoptosis: facts and hypotheses. Oncogene 22: 8619-8627, 2003.
104. Rodgers GM and Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 75: 895-901, 1990.
105. Rodgers GM and Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 77: 1909-1916, 1986.
106. Rutkowski DT and Kaufman RJ. A trip to the ER: coping with stress. Trends Cell Biol 14: 20-28, 2004.
107. Sambrook JF. The involvement of calcium in transport of secretory proteins from the endoplasmic reticulum. Cell 61: 197-199, 1990.
108. Samet JM, Graves LM, Quay J, Dailey LA, Devlin RB, Ghio AJ, Wu W, Bromberg PA, and Reed W. Activation of MAPKs in human bronchial epithelial cells exposed to metals. Am J Physiol 275: L551-L558, 1998.
109. Sartorio R, Carrozzo R, Corbo L, and Andria G. Protein-bound plasma homocyt(e)ine and identification of heterozygotes for cystathionine β-synthase deficiency. J Inherit Metab Dis 9: 25-29, 1986.
110. Sauls DL, Lockhart E, Warren ME, Lenkowski A, Wilhelm SE, and Hoffman M. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. Biochemistry 45: 2480-2487, 2006.
111. Schroder M and Kaufman RJ. ER stress and the unfolded protein response. Mutat Res 569: 29-63, 2005.
112. Sengupta S, Chen H, Togawa T, DiBello PM, Majors AK, Büdy B, Ketterer ME, and Jacobsen DW. Albumin thiolate anion is an intermediate in the formation of albumin-S-S-homocysteine. J Biol Chem 276: 30111-30117, 2001.
113. Sengupta S, Wehbe C, Majors AK, Ketterer ME, DiBello PM, and Jacobsen DW. Relative roles of albumin and ceruloplasmin in the formation of homocysteine, homocysteine-cysteine mixed disulfide, and cystine in circulation. J Biol Chem 276: 46896-46904, 2001.
114. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PWF, and Wolf PA. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346: 476-483, 2002.
115. Smolin LA and Benevenga NJ. The use of cyst(e)ine in the removal of protein-bound homocysteine. Am J Clin Nutr 39: 730-737, 1984.
116. Stehouwer CDA, Gall MA, Hougaard P, Jakobs C, and Parving HH. Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria. Kidney Int 55: 308-314, 1999.
117. Stuhlinger MK, Tsao PS, Her J-H, Kimoto M, Balint RF, and Cooke JP. Homocysteine impairs the nitric oxide synthase pathway role of asymmetric dimethylarginine. Circulation 104: 2569-2575, 2001.
118. Taylor LM Jr, Moneta GL, Sexton GJ, Schuff RA, Porter JM, and Investigators HPAS. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg 29: 8-19, 1999.
119. Théberge R, Conners L, Skinner M, and Costello CE. Characterization of transthyretin from serum using immunoprecipitation, HPLC/electrospray ionization and matrix-assisted laser desorption/ionization mass spectrometry. Anal Chem 71: 452-459, 1999.
120. Tsai J-C, Perrella MA, Yoshizumi M, Hsieh C-M, Haber E, Schlegel R, and Lee M-E. Promotion of vascular smooth muscle growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A 91: 6369-6373, 1994.
121. Tsujimoto A, Nyunoya H, Morita T, Sato T, and Shimotohno K. Isolation of cDNAs for DNA-binding proteins which specifically bind to a tax-responsive enhancer element in the long terminal repeat of human T-cell leukemia virus type I. J Virol 65: 1420-1426, 1991.
122. Undas A, Brozek J, Jankowski M, Siudak Z, Szczeklik A, and Jakubowski H. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Arterioscler Thromb Vasc Biol 26: 1397-1404, 2006.
123. Undas A, Williams EB, Butenas S, Orfeo T, and Mann KG. Homocysteine inhibits inactivation of factor Va by activated protein C. J Biol Chem 276: 4389-4397, 2001.
124. Upchurch GR Jr, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF Jr, and Loscalzo J. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 272: 17012-17017, 1997.
125. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der Klift M, de Jonge R, Lindemans J, de Groot LC, Hofman A, Witteman JC, van Leeuwen JP, Breteler MM, Lips P, Pols HA, and Uitterlinden AG. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 350: 2033-2041, 2004.
126. Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK, Monsen ALB, and Ueland PM. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine Study. Am J Clin Nutr 71: 962-968, 2000.
127. Wang H, Jiang X, Yang F, Gaubatz JW, Ma L, Magera MJ, Yang X, Berger PB, Durante W, Pownall HJ, and Schafer AI. Hyperhomocysteinemia accelerates atherosclerosis in cystathionine β-synthase and apolipoprotein E double knock-out mice with and without dietary perturbation. Blood 101: 3901-3907, 2003.
128. Watson LM, Chan AK, Berry LR, Li J, Sood SK, Dickhout JG, Xu L, Werstuck GH, Bajzar L, Klamut HJ, and Austin RC. Overexpression of the 78-kDa glucose-regulated protein/immunoglobulin-binding protein (GRP78/BiP) inhibits tissue factor procoagulant activity. J Biol Chem 278: 17438-17447, 2003.
129. Weiss N. Mechanisms of increased vascular oxidant stress in hyperhomocysteinemia and its impact on endothelial function. Curr Drug Metab 6: 27-36, 2005.
130. Weiss N, Heydrick S, Zhang YY, Bierl C, Cap A, and Loscalzo J. Cellular redox state and endothelial dysfunction in mildly hyperhomocysteinemic cystathionine β-synthase-deficient mice. Arterioscler Thromb Vasc Biol 22: 34-41, 2002.
131. Weiss N, Zhang Y-Y, Heydrick S, Bierl C, and Loscalzo J. Overexpression of cellular glutathione peroxidase rescues homocyst( e)ine-induced endothelial dysfunction. Proc Natl Acad Sci U S A 98: 12503-12508, 2001.
132. Werstuck GH, Lentz SR, Dayal S, Hossain GS, Sood SK, Shi YY, Zhou J, Maeda N, Krisans SK, Malinow MR, and Austin RC. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 107: 1263-1273, 2001.
133. Wilcken DEL and Wilcken B. The pathogenesis of coronary artery disease: a possible role for methionine metabolism. J Clin Invest 57: 1079-1082, 1976.
134. Wild SH, Fortmann SP, and Marcovina SM. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford five-city project participants. Arterioscler Thromb Vasc Biol 17: 239-245, 1997.
135. Wiley VC, Dudman NPB, and Wilcken DEL. Free and protein-bound homocysteine and cysteine in cystathionine β-synthase deficiency: Interrelations during short- and long-term changes in plasma concentrations. Metabolism 38: 734-739, 1989.
136. Ye J, Rawson RB, Komuro R, Chen X, Dave UP, Prywes R, Brown MS, and Goldstein JL. ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol Cell 6: 1355-1364, 2000.
137. Zhang C, Cai Y, Adachi MT, Oshiro S, Aso T, Kaufman RJ, and Kitajima S. Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. J Biol Chem 276: 35867-35874, 2001.
138. Zhang K and Kaufman RJ. The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology 66: S102-S109, 2006.
139. Zhao L and Ackerman SL. Endoplasmic reticulum stress in health and disease. Curr Opin Cell Biol 18: 444-452, 2006.
140. Zhou J, Moller J, Danielsen CC, Bentzon J, Ravn HB, Austin RC, and Falk E. Dietary supplement with methionine and homocysteine promotes early atherogenesis but not plaque rupture in apoE-deficient mice. Arterioscler Thromb Vasc Biol 21: 1470-1476, 2001.